The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 653.50
Bid: 653.50
Ask: 655.50
Change: 11.00 (1.71%)
Spread: 2.00 (0.306%)
Open: 652.50
High: 654.00
Low: 652.50
Prev. Close: 642.50
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Alliance with McNeil Nutritionals

13 Feb 2014 07:00

13 February 2014 – Tate & Lyle PLC

New Alliance with McNeil Nutritionals

Tate & Lyle PLC announces today the latest phase of its 30-year Sucralose partnership with McNeil Nutritionals, LLC through the establishment of a renewed SPLENDA® Alliance. The focus for the renewed partnership will be the development and growth of the global market for Sucralose and the SPLENDA® Brand. This is a natural evolution of the long-term partnership that has nurtured the success of Sucralose and the SPLENDA® Brand, following the strategic realignment announced in 2004. At that time, Tate & Lyle took over McNeil Nutritionals’ Sucralose manufacturing assets and responsibility for worldwide food and beverage ingredient sales, while McNeil Nutritionals, LLC retained ownership of the SPLENDA® Brand and the retail and food service business.

Both companies will partner on the continued development and promotion of the SPLENDA® Brand and Sucralose, including ingredient and brand protection initiatives. The new arrangements include terms for ongoing supply upon expiration of the current agreement. The partnership will continue to leverage the strengths of each company and ensure the continued growth of the SPLENDA® Sucralose business and the SPLENDA® Brand globally.

Javed Ahmed, Chief Executive of Tate & Lyle, said:

“We are delighted about the continuation of our established 30-year partnership with McNeil Nutritionals and look forward to the next phase of the relationship. Alongside our global partners, we are committed to growing the global market for SPLENDA® Sucralose, which remains the high intensity sweetener of choice due to its superior taste profile and stability, enabling its use across a broad range of applications. Together, we will continue to ensure that the SPLENDA® Brand remains the benchmark within the industry for quality, reliability and innovation well into the future.”

END

Notes to editors: selected historical background relating to SPLENDA® Sucralose based on previous disclosures

1976 Discovery of sucralose by Tate & Lyle and Queen Elizabeth's College, University of London researchers

1980 First agreements between Tate & Lyle and Johnson & Johnson. These were patent licences creating exclusive geographical territories for the two companies – for Johnson & Johnson, North America (excluding Canada), South America, the Caribbean, the Middle East and Australasia; for Tate & Lyle, Europe, Canada, Africa and Asia

1991 First approval granted for sucralose (Canada)

1998 US FDA approval for sucralose obtained

2000 McNeil's McIntosh plant, the world’s first integrated sucralose production facility, mechanically complete

2001 Global Sucralose Alliance announced, providing for the realignment of Tate & Lyle and McNeil sucralose activities. Under the realigned arrangements, Tate & Lyle to act as exclusive broker for sucralose ingredient sales in certain key markets; McNeil to market SPLENDA® Brand tabletop products exclusively

2003 EU approval for sucralose

2004 Further Sucralose realignment with Tate & Lyle becoming the sole manufacturer and responsible for worldwide ingredient sales of SPLENDA® Sucralose to food and beverage manufacturers and McNeil responsible for the worldwide SPLENDA® Brand retail and food service business. As part of the realignment, Tate & Lyle acquired McNeil’s sucralose manufacturing plant and other ingredient business assets for £71 million

The realignment included arrangements by which each company would participate in the success of the other. In the case of Tate & Lyle, deferred consideration was payable to McNeil for the first five years dependent on Tate & Lyle’s sucralose ingredient sales (above a target level). Tate & Lyle in turn received payments from McNeil based on McNeil sales of sucralose tabletop products for 10 years from the date of completion of the transaction. The aggregate amount paid to McNeil over the five years by Tate & Lyle amounted to £37 million. Assuming receipt of the £7 million payment anticipated in respect of the year ending 31 March 2014, the final such payment, the aggregate of the payments received from McNeil will amount to £75 million

2014 New SPLENDA® Alliance announced

For more information contact Tate & Lyle PLC:

Mathew Wootton, Group VP, Investor and Media RelationsTel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7500 100 320

Andrew Lorenz (FTI Consulting), Media RelationsTel: +44 (0) 20 7269 7113 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, operating from over 30 production facilities around the world.

Tate & Lyle operates through two global business units, Speciality Food Ingredients and Bulk Ingredients, supported by the Innovation and Commercial Development group. The Group's strategy is to become the leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our food systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2013, Tate & Lyle sales totalled £3.3 billion. http://www.tateandlyle.com.

SPLENDA® is a trademark of McNeil Nutritionals, LLC.

Copyright Business Wire 2014

Date   Source Headline
25th Apr 20243:45 pmRNSHolding(s) in Company
24th Apr 20247:00 amRNSDirectorate Change
22nd Apr 20242:30 pmRNSDirector/PDMR Shareholding
19th Apr 202410:15 amRNSHolding(s) in Company
17th Apr 20244:15 pmRNSHolding(s) in Company
17th Apr 202410:30 amRNSHolding(s) in Company
15th Apr 202410:30 amRNSHolding(s) in Company
10th Apr 20243:45 pmRNSHolding(s) in Company
8th Apr 202411:15 amRNSHolding(s) in Company
5th Apr 20243:45 pmRNSHolding(s) in Company
4th Apr 20244:15 pmRNSHolding(s) in Company
4th Apr 202412:30 pmRNSHolding(s) in Company
4th Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 202412:45 pmRNSTotal Voting Rights
2nd Apr 202411:30 amRNSHolding(s) in Company
28th Mar 202411:45 amRNSHolding(s) in Company
25th Mar 202411:45 amRNSHolding(s) in Company
21st Mar 20244:10 pmRNSHolding(s) in Company
20th Mar 20243:00 pmRNSHolding(s) in Company
20th Mar 202412:00 pmRNSHolding(s) in Company
19th Mar 20242:00 pmRNSHolding(s) in Company
13th Mar 20244:00 pmRNSHolding(s) in Company
12th Mar 20244:24 pmRNSHolding(s) in Company
12th Mar 20244:22 pmRNSHolding(s) in Company
7th Mar 20247:00 amRNSDirectorate Change
4th Mar 20242:00 pmRNSDirector/PDMR Shareholding
4th Mar 20241:45 pmRNSHolding(s) in Company
28th Feb 20242:30 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSTrading Statement
1st Feb 202412:00 pmRNSTotal Voting Rights
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202412:00 pmRNSBlock listing Interim Review
8th Dec 202311:45 amRNSDirector/PDMR Shareholding
6th Dec 202310:30 amRNSHolding(s) in Company
27th Nov 20234:15 pmRNSHolding(s) in Company
23rd Nov 20232:30 pmRNSHolding(s) in Company
20th Nov 202310:00 amRNSHolding(s) in Company
9th Nov 20237:00 amRNSHalf-year Report
8th Nov 20237:00 amRNSDirectorate Change
23rd Oct 202310:30 amRNSHolding(s) in Company
16th Oct 202310:30 amRNSHolding(s) in Company
13th Oct 202310:30 amRNSHolding(s) in Company
12th Oct 202311:00 amRNSHolding(s) in Company
2nd Oct 202310:23 amRNSDirector Declaration
1st Sep 202311:00 amRNSTotal Voting Rights
25th Aug 20233:45 pmRNSHolding(s) in Company
17th Aug 20234:30 pmRNSHolding(s) in Company
15th Aug 20234:30 pmRNSHolding(s) in Company
10th Aug 20234:00 pmRNSHolding(s) in Company
7th Aug 202312:15 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.